Antibody firm AxioMx said this week that it has completed its initial financing round, raising more than $2 million from investors including Connecticut Innovations, Elm Street Ventures, and the company's founders.

Founded this year, AxioMx specializes in the discovery and development of custom recombinant antibodies, offering services including epitope mapping and antigen design as well as antibody screening, affinity maturation, optimization, and production.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.